Leap to present on Phase 2 study at ASCO

 30% ORR and 93% DCR across heterogenous second-line CRC patients

treated with DKN-01 plus bevacizumab and chemotherapy

Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with
46% ORR, 100% DCR, and preliminary median PFS of 9.4 months.

Leap to host conference call to report additional clinical data including further subgroup analyses
on Tuesday, January 23, 2024 at 8:30 a.m. ET

Leap's management team, together with Dr. Pelster and Dr. Wainberg, will host a conference call on Tuesday, January 23, 2024 at 8:30 a.m. Eastern Time to further discuss the data. The conference call will be broadcast live in listen-only mode and can be accessed via the website URL: https://edge.media-server.com/mmc/p/q5zrz568. A replay of the event will also be available for a limited time on the Investors page of the Company's website at https://investors.leaptx.com/.

https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-new-clinical-data-from-part-a-of-defiance-study-at-the-2024-asco-gastrointestinal-cancers-symposium-302036326.html